Hasan Fattah 3/19/2013
|
|
- Dale Maxwell
- 5 years ago
- Views:
Transcription
1 Hasan Fattah 3/19/2013
2 AASK trial Rational: HTN is a leading cause of (ESRD) in the US, with no known treatment to prevent progressive declines leading to ESRD. Objective: To compare the effects of 2 levels of (BP) control and 3 antihypertensive drug classes on (GFR) decline in HTN. Design Randomized with enrollment from Participants: 1094 AA aged 18 to 70 years with hypertensive renal disease (GFR, ml/min per 1.73 m 2 ) were recruited from 21 clinical centers throughout the US and followed up for 3 to 6.4 years.
3 Interventions: Participants were randomly assigned to 1 of 2 mean arterial pressure goals: to 107 mm Hg (usual; n = 554) mm Hg or less (lower; n = 540), initial treatment with either a β-blocker (metoprolol mg/d; n = 441), an ACEi (ramipril mg/d; n = 436) or a calcium channel blocker, (amlodipine 5-10 mg/d; n = 217). Main Outcome Measures : Rate of change in GFR (GFR slope); clinical composite outcome of reduction in GFR by 50% or more (or 25 ml/min per 1.73 m 2 ) from baseline, ESRD, or death. Three primary treatment comparisons were specified: lower vs usual BP goal; ramipril vs metoprolol; and amlodipine vs metoprolol.
4 JAMA. 2002
5 JAMA. 2002
6 JAMA. 2002
7 JAMA. 2002
8 Proposal of existence of a major nephropathy susceptibility gene underlying several common forms of kidney disease in African Americans in the early 1990s. Freedman et al Am J Kidney Dis. 1993
9 Kopp et al and Kao et al first applied MALD to kidney disease and detected an impressive genetic association between the non-muscle myosin heavy chain 9 gene (MYH9) E1 haplotype and idiopathic FSGS, nondiabetic ESRD, and HIVAN in African Americans Within two years Genovese, Freedman and colleagues demonstrated that two coding variants in APOL1 (termed G1: non-synonymous coding variant 342 G:384 M and G2: a 6 bp deletion) had stronger genetic association with nondiabetic nephropathy than the MYH9 E1 haplotype
10 MALD
11 APOL1 coding variants underlie a spectrum of kidney diseases, including that attributed to hypertension (labeled arteriolar or hypertensive nephrosclerosis), focal segmental glomerulosclerosis, and HIVassociated nephropathy
12 205 AA with biopsy proven FSGS but no FH with 180 AA controls. Genovese et al Science 2010
13 Genotype/Haplotype frequencies for FSGS cases/esrd and controls Genovese et al Science 2010
14 Kopp et al J, Am Nephrol 2011
15 Kopp et al J, Am Nephrol 2011
16 In conclusion: APOL1 genetic variation is a powerful contributor to risk for FSGS and HIVAN. The attributable risk is quantitatively comparable to the role of smoking in non-small-cell lung cancer risk. While only 12 to 13% of African Americans carry two APOL1 risk alleles, these individuals have an estimated 4% lifetime risk for FSGS, and when they develop FSGS, they tend to progress to ESKD rapidly.
17 Clinical Applications of APOL1 Genotyping in Renal Transplantation Kidneys donated by AAs are known to function for shorter periods of time than kidneys donated by European Americans Meier-Kriesche et al Kidney Int 2000
18 The APOL1 gene and allograft survival after kidney transplantation: single center study From March 24, 1998 through September 12, AA deceased organ donors kidneys recovered and typing material procured or delivered to the Wake Forest University Baptist Medical Center (WFUBMC) for transplantation purpose kidney transplant patients were followed longitudinally at our center for at least 1 year and form the study sample. Outcome of interest: time to graft failure Reeves-Daniel et al, A J of transplantation 2011
19 Demographic characteristics of renal allograft donors and recipients Variables Number of APOL1 G1-G2 nephropathy risk variants from kidney donor Two N = 22 Zero or 1 N = 114 p Value Donor age (years) 43.7 ± ± Donor gender (% male) Terminal serum creatinine (mg/dl) 1.34 ± ± Donor African ancestry%) 0.77 ± ± Cold ischemia time (hours) 22.5 ± ± HLA mismatch (N) 4.2 ± ± Recipient gender (% male) Recipient age (years) 45.2 ± ± Recipient race (% African American) Diabetic ESRD in recipients (%)
20 Fully adjusted model for renal allograft survival Parameter APOL1 G1/G2 (2 vs. 0/1 copies) Parameter estimate Standard error p Value Hazard ratio African ancestry Recipient age Gender (female) Donor criteria (standard) HLA mismatch Cold ischemia time PRA* > 0%
21 Renal allograft survival according to APOL1 genotype Reeves-Daniel et al, A J of transplantation 2011
22 Multivariate analysis was repeated excluding graft failures due to hyperacute rejection, two APOL1 G1/G2 risk variants in donors (HR 2.32, p = 0.028) and number of HLA mismatches (HR 1.68, p = 0.025) remained significantly associated with graft survival
23 Outcomes: Differences in graft survival were seen after approximately 20 months. African ancestry did not significantly impact renal allograft survival after transplantation shorter renal allograft survival rates seen in kidneys donated by AAs relative to Caucasians could be substantially related to variation in APOL1.
24 Limitation: Small size sample Lack of APOL1 genotype in recipients Single txp center
25 Does The APOL1 Genotype of AA Kidney Transplant Recipients Impact Allograft Survival Subjects: kidney transplant recipients at the Brigham and Women's Hospital and the University of Alabama at Birmingham, transplanted between 1988 and Of the original cohort (n = 424) only 124 DNA samples identified from kidney transplant recipients of recent African ancestry. Retrospective primary outcome: allograft survival, Differences between subjects in the 2 risk allele group and the 0 or 1 risk allele. Am J Transplant 2012
26 Number of APOL1 genotypes organized by native end-stage renal disease in kidney transplant recipients DM FSGS GN HTN Other/UN K Total (%) WT/WT (21) WT/G (20.2) WT/G (10.1) G1/G (24.2) G1/G (22.7) G2/G (1.7) Total (%) 24 (20.2) 15 (12.6) 17 (14.3) 31 (26.1) 32 (26.9) 119 Am J Transplant 2012
27 Characteristics of kidney transplant recipients 2 Risk alleles 0 or 1 Risk alleles Number of subjects 58 (48.7%) 61 (51.3%) Mean age at transplant (years) p value Cause of ESRD Attributed to HTN Diabetes mellitus 7 19 FSGS 9 6 Type of donor kidney Deceased Living related Donor ethnicity is Black 25 (43.1%) 20 (32.8%) Allograft loss (%) 13 (22.4%) 13 (21.3%) Allograft loss censored by death %) 13 (22.4%) 11 (18.0%) Patient death 1 2 Acute rejection within 1-year posttransplant 2 2
28 Allograft survival of subjects with 0, 1 or 2 risk alleles Am J Transplant 2012
29 having 2 APOL1 risk alleles should not be an impediment to kidney transplantation Future work needs to be done to study the genotypes of kidney transplant recipients and donors together.
30 Potential Mechanisms of APOL1-Associated Nephropathy
31 FIRST PROPOSAL Altered plasma HDL particle concentrations could lead to kidney disease via damage to the renal microcirculation*. ApoL1 is expressed in the liver and may play a role in modifying production of nascent HDL particles that are destined to become the medium-sized HDL subclass upon maturation.
32 Plasma HDL particle subclass concentrations were compared in 73 AA based on APOL1 genotypes to detect differences potentially contributing to renal disease. Freedman et al Nephrol Dial Transplant (2011)
33 Mean (SD) plasma HDL subclass concentrations (lmol/l) HDL subclass No APOL1 risk variants One APOL1 risk variants Two APOL1 risk variants P-value * Unadjusted Adjusted N = 20 N = 17 N = 36 Total HDL particles 36.8 ± 7.6 (34.6) 33.1 ± 7.7 (32.1) 35.6 ± 7.5 (34.3) Large HDL particles ( nm) 5.7 ± 4.1 (4.9) 5.2 ± 2.9 (4.4) 7.0 ± 5.2 (6.3) Medium HDL particles ( nm) 13.1 ± 8.2 (10.7) 10.1 ± 5.5 (8.5) 9.0 ± 5.6 (7.9) Small HDL particles ( nm) 18.1 ± 6.1 (18.5) 17.8 ± 6.6 (17.4) 19.6 ± 6.8 (20.1) Freedman et al Nephrol Dial Transplant (2011)
34 SECOND POSSIBILITY ApoL1 variant proteins bind to HDL particles less avidly, circulate freely, cross the glomerular filtration barrier, and lead to glomerulosclerosis and/or IFTA. This hypothesis is strengthened by the observation that Circulating ApoL1 proteins have been implicated in rapidly recurring FSGS after kidney transplantation; a syndrome that can be improved with plasmapheresis. Gohh et al Am J Transplant. 2005
35 THIRD ONE APOL1 variants may induce apoptosis or autophagy in podocytes, with resultant FSGS or FGGS. messenger RNA encoding ApoL1 protein is expressed in cultured human podocytes and other renal cell types.
36 Apolipoprotein L1, a Novel Bcl-2 Homology Domain 3-only Lipid-binding Protein, Induces Autophagic Cell Death* ApoL1 shares structural and functional similarities with the Bcl2 family of proteins involved in apoptosis. the apoptosis regulating B-cell lymphoma 2 gene (Bcl2) is closely related to APOL1
37 Time- and dose-dependent induction of apol1 and cell death in DLD-1.ApoL1 cells JOURNAL OF BIOLOGICAL CHEMISTRY 2008
38 BH3 domain deletion construct of apol1 failed to induce cell death in DLD-1 cells JOURNAL OF BIOLOGICAL CHEMISTRY 2008
39 ApoL1-induced cell death is through autophagy, not by apoptosis
40
41
42
Anna Vinnikova, MD APOL1
Anna Vinnikova, MD APOL1 I have no relevant financial relationships with commercial interests But I have a passionate interest in the following problem: National decline in Nephrology Fellowship applications
More informationBiological Basis for Increased Risk of Graft Loss in African American (AA)-APOL1 and Beyond
Biological Basis for Increased Risk of Graft Loss in African American (AA)-APOL1 and Beyond Jonah Odim, MBA, MD, PhD Chief, Clinical Transplantation Division of Allergy, Immunology, and Transplantation
More informationCase # 2 3/27/2017. Disclosure of Relevant Financial Relationships. Clinical history. Clinical history. Laboratory findings
Case # 2 Christopher Larsen, MD Arkana Laboratories Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to influence or control the content
More informationChapter 6: Transplantation
Chapter 6: Transplantation Introduction During calendar year 2012, 17,305 kidney transplants, including kidney-alone and kidney plus at least one additional organ, were performed in the United States.
More informationALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR)
1 RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) 6 / 5 / 1006-1 2 Introduction Hypertension is the second most common cause of end-stage
More informationSELECTED ABSTRACTS. All (n) % 3-year GS 88% 82% 86% 85% 88% 80% % 3-year DC-GS 95% 87% 94% 89% 96% 80%
SELECTED ABSTRACTS The following are summaries of selected posters presented at the American Transplant Congress on May 5 9, 2007, in San Humar A, Gillingham KJ, Payne WD, et al. Review of >1000 kidney
More informationLessons learned from AASK (African-American Study of Kidney Disease and Hypertension)
Lessons learned from AASK (African-American Study of Kidney Disease and Hypertension) Janice P. Lea, MD, MSc, FASN Professor of Medicine Chief Medical Director of Emory Dialysis ASH Clinical Specialist
More informationReducing proteinuria
Date written: May 2005 Final submission: October 2005 Author: Adrian Gillin Reducing proteinuria GUIDELINES a. The beneficial effect of treatment regimens that include angiotensinconverting enzyme inhibitors
More informationKidney Transplant Outcomes In Elderly Patients. Simin Goral MD University of Pennsylvania Medical Center Philadelphia, Pennsylvania
Kidney Transplant Outcomes In Elderly Patients Simin Goral MD University of Pennsylvania Medical Center Philadelphia, Pennsylvania Case Discussion 70 year old Asian male, neuropsychiatrist, works full
More informationHHS Public Access Author manuscript Kidney Int. Author manuscript; available in PMC 2015 September 01.
Kidney transplant results in children: progress made, but blacks lag behind Vikas R. Dharnidharka, MD, MPH 1 and Michael E. Seifert, MD 1,2 1 Division of Pediatric Nephrology, Washington University School
More informationThe New Kidney Allocation System: What You Need to Know. Anup Patel, MD Clinical Director Renal and Pancreas Transplant Division Barnabas Health
The New Kidney Allocation System: What You Need to Know Anup Patel, MD Clinical Director Renal and Pancreas Transplant Division Barnabas Health ~6% of patients die each year on the deceased donor waiting
More informationTuesday Conference 7/23/2013. Hasan Fattah
Tuesday Conference 7/23/2013 Hasan Fattah 48 AA male, PMH: HTN, proteinuria since 2009, sent from primary clinic for high Cr evaluation (7.1), last known of 1.1 in 2010 associated with sub-nephrotic range
More informationCase Presentation Turki Al-Hussain, MD
Case Presentation Turki Al-Hussain, MD Director, Renal Pathology Chapter Saudi Society of Nephrology & Transplantation Consultant Nephropathologist & Urological Pathologist Department of Pathology & Laboratory
More informationTransplant Nephrology Update: Focus on Outcomes and Increasing Access to Transplantation
Transplant Nephrology Update: Focus on Outcomes and Increasing Access to Transplantation Titte R Srinivas, MD, FAST Medical Director, Kidney and Pancreas Transplant Programs Objectives: Describe trends
More informationBK virus infection in renal transplant recipients: single centre experience. Dr Wong Lok Yan Ivy
BK virus infection in renal transplant recipients: single centre experience Dr Wong Lok Yan Ivy Background BK virus nephropathy (BKVN) has emerged as an important cause of renal graft dysfunction in recent
More informationBlood Pressure Monitoring in Chronic Kidney Disease
Blood Pressure Monitoring in Chronic Kidney Disease Aldo J. Peixoto, MD FASN FASH Associate Professor of Medicine (Nephrology), YSM Associate Chief of Medicine, VACT Director of Hypertension, VACT American
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Blood Pressure Control role of specific antihypertensives
Blood Pressure Control role of specific antihypertensives Date written: May 2005 Final submission: October 2005 Author: Adrian Gillian GUIDELINES a. Regimens that include angiotensin-converting enzyme
More informationDonor-derived Cell-free DNA Improves DSA-informed Diagnosis of ABMR in Kidney Transplant Patients
Donor-derived Cell-free DNA Improves DSA-informed Diagnosis of ABMR in Kidney Transplant Patients Stanley C. Jordan, MD Director, Division of Nephrology Medical Director, Kidney Transplant Program Medical
More informationNAPRTCS Annual Transplant Report
North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 2014 Annual Transplant Report This is a privileged communication not for publication. TABLE OF CONTENTS PAGE II TRANSPLANTATION Section
More informationRENAL TRANSPLANTATION HAS
ORIGINAL CONTRIBUTION Arterial Hypertension and Renal Allograft Survival Kevin C. Mange, MD Borut Cizman, MD Marshall Joffe, MD, PhD Harold I. Feldman, MD, MSCE Context Several observational studies have
More informationChronic kidney disease in African Americans: Puzzle pieces are falling into place
ADDRESSING DISPARITIES IN HEALTHCARE LEARNING OBJECTIVE: Readers will recognize recent advances in the understanding of chronic kidney disease in African Americans JOSEPH V. NALLY, JR, MD Former Director,
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationKerry Cooper M.D. Arizona Kidney Disease and Hypertension Center April 30, 2009
Kerry Cooper M.D. Arizona Kidney Disease and Hypertension Center April 30, 2009 DR. KERRY COOPER IS ON THE SPEAKER BUREAU OF AMGEN, ABBOTT, GENZYME, SHIRE, AND BMS DR. COOPER IS ALSO INVOLVED IN CLINICAL
More informationSpecial Challenges and Co-Morbidities
Special Challenges and Co-Morbidities Renal Disease/ Hypertension/ Diabetes in African-Americans M. Keith Rawlings, MD Medical Director Peabody Health Center AIDS Arms, Inc Dallas, TX Chair, Internal Medicine
More informationNAPRTCS Annual Transplant Report
North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 2010 Annual Transplant Report This is a privileged communication not for publication. TABLE OF CONTENTS PAGE I INTRODUCTION 1 II
More informationLIVE KIDNEY DONOR RISK PREDICTION ; NEW PARADIGM, NEW CALCULATORS PEDRAM AHMADPOOR MD
LIVE KIDNEY DONOR RISK PREDICTION ; NEW PARADIGM, NEW CALCULATORS PEDRAM AHMADPOOR MD Outline: PART 1 : Update on safety of nephrectomy for living donor candidate PART 2 : Latest guideline recommendation
More informationProgress in Pediatric Kidney Transplantation
Send Orders for Reprints to reprints@benthamscience.net The Open Urology & Nephrology Journal, 214, 7, (Suppl 2: M2) 115-122 115 Progress in Pediatric Kidney Transplantation Jodi M. Smith *,1 and Vikas
More informationLiterature Review Transplantation
Literature Review 2010- Transplantation Alexander Wiseman, M.D. Associate Professor, Division of Renal Diseases and Hypertension Medical Director, Kidney and Pancreas Transplant Programs University of
More informationSteroid Minimization: Great Idea or Silly Move?
Steroid Minimization: Great Idea or Silly Move? Disclosures I have financial relationship(s) within the last 12 months relevant to my presentation with: Astellas Grants ** Bristol Myers Squibb Grants,
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More informationManagement of Hypertensive Chronic Kidney Disease: Role of Calcium Channel Blockers. Robert D. Toto, MD
R e v i e w P a p e r Management of Hypertensive Chronic Kidney Disease: Role of Calcium Channel Blockers Robert D. Toto, MD Both the prevalence and incidence of end-stage renal disease have been increasing
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationAPOL1 polymorphisms and development of CKD in an identical twin donor and recipient pair.
APOL1 polymorphisms and development of CKD in an identical twin donor and recipient pair. Tomek Kofman, Vincent Audard, Céline Narjoz, Olivier Gribouval, Marie Matignon, Claire Leibler, Dominique Desvaux,
More informationAssociation of the MYH9 gene polymorphisms with chronic renal disease secondary to hypertensive nephrosclerosis, in a Caucasian population
American Journal of Internal Medicine 2014; 2(6): 95-101 Published online October 30, 2014 (http://www.sciencepublishinggroup.com/j/ajim) doi: 10.11648/j.ajim.20140206.11 ISSN: 2330-4316 (Print); ISSN:
More informationTransplant Options for Patients: Choices and Consequences. Olwyn Johnston Medical Director Kidney Transplantation Vancouver General Hospital
Transplant Options for Patients: Choices and Consequences Olwyn Johnston Medical Director Kidney Transplantation Vancouver General Hospital BC Kidney Days October 6 th 2017 Non contributory Conflict of
More informationOptimal blood pressure targets in chronic kidney disease
Optimal blood pressure targets in chronic kidney disease Pr. Michel Burnier Service of Nephrology and Hypertension University Hospital Lausanne Switzerland Evidence-Based Guideline for the Management
More informationPredicting and changing the future for people with CKD
Predicting and changing the future for people with CKD I. David Weiner, M.D. Co-holder, C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University
More informationAre two better than one?
Are two better than one? Disclosures Ryutaro Hirose, MD Professor in Clinical Surgery University of California, San Francisco I have no relevant disclosures related to this presentation The PROBLEM There
More informationLong-term Non-ESRD Kidney Donor Risks. Arthur Matas Dept Surgery University of Minnesota
Long-term Non-ESRD Kidney Donor Risks Arthur Matas Dept Surgery University of Minnesota Conflict of Interest Disclosure I have no relevant financial relationships to disclose No off label use will be discussed
More information21 st Budapest Nephrology School
Genetics of non-diabetic kidney disease 21 st Budapest Nephrology School Barry I. Freedman, MD, FACP John H. Felts III Professor (Internal Medicine) Chief, Section on Nephrology Podocyte disorders β3 integrin
More informationUpdate on HIV-Related Kidney Diseases. Agenda
Update on HIV-Related Kidney Diseases ANDY CHOI THE MEDICAL MANAGEMENT OF HIV/AIDS DECEMBER 15, 2006 Agenda 1. EPIDEMIOLOGY: A) END STAGE RENAL DISEASE (ESRD) B) CHRONIC KIDNEY DISEASE (CKD) 2. HIV-ASSOCIATED
More informationUniversity of Groningen. Evaluation of renal end points in nephrology trials Weldegiorgis, Misghina Tekeste
University of Groningen Evaluation of renal end points in nephrology trials Weldegiorgis, Misghina Tekeste IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish
More informationKidney Transplant in the Elderly. Robert Santella, M.D., F.A.C.P.
Kidney Transplant in the Elderly! Robert Santella, M.D., F.A.C.P. Incident Rate of ESRD by Age Age 75+ 65-74 From US Renal Data System, 2012 Should there be an age limit? Various guidelines: Canadian,
More informationPredictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
Pediatr Transplantation 2013: 17: 436 440 2013 John Wiley & Sons A/S. Pediatric Transplantation DOI: 10.1111/petr.12095 Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
More informationConsidering the early proactive switch from a CNI to an mtor-inhibitor (Case: Male, age 34) Josep M. Campistol
Considering the early proactive switch from a CNI to an mtor-inhibitor (Case: Male, age 34) Josep M. Campistol Patient details Name DOB ESRD Other history Mr. B.I.B. 12 January 1975 (34yo) Membranous GN
More informationThe Seventh Report of the Joint National Commission
The Effect of a Lower Target Blood Pressure on the Progression of Kidney Disease: Long-Term Follow-up of the Modification of Diet in Renal Disease Study Mark J. Sarnak, MD; Tom Greene, PhD; Xuelei Wang,
More informationACEIs / ARBs NDHP dihydropyridine ( DHP ) ACEIs ARBs ACEIs ARBs NDHP. ( GFR ) 60 ml/min/1.73m ( chronic kidney disease, CKD )
005 16 175-180 1 1 ( chronic kidney disease, CKD ) 003 ( end-stage renal disease, ESRD ) Angiotensin-converting enzyme inhibitors ( ) angiotensin receptor blockers ( ) nondihydropyridine ( NDHP ) / NDHP
More informationDiabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin
Diabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin Disclosures I have no financial relationship with the manufacturers of any commercial product discussed during this
More informationORIGINAL ARTICLE. Eric F. Martin, 1 Jonathan Huang, 3 Qun Xiang, 2 John P. Klein, 2 Jasmohan Bajaj, 4 and Kia Saeian 1
LIVER TRANSPLANTATION 18:914 929, 2012 ORIGINAL ARTICLE Recipient Survival and Graft Survival are Not Diminished by Simultaneous Liver-Kidney Transplantation: An Analysis of the United Network for Organ
More informationHYPERTENSION IN CKD. LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL
HYPERTENSION IN CKD LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL Stages in Progression of Chronic Kidney Disease and Therapeutic Strategies Complications Normal Increased risk Damage GFR
More informationDiabetic Nephropathy
Diabetic Nephropathy Objectives: Know what Diabetic Nephropathy means. Know how common is Diabetic nephropathy in Saudi Arabia and to appreciate how bad are this complications. Know the risk factors of
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationABSTRACT. n engl j med 369;23 nejm.org december 5,
The new england journal of medicine established in 1812 december 5, 2013 vol. 369 no. 23 APOL1 Risk Variants, Race, and Progression of Chronic Kidney Disease Afshin Parsa, M.D., M.P.H., W.H. Linda Kao,
More informationKidney and Pancreas Transplantation in the United States,
American Journal of Transplantation 2006; 6 (Part 2): 1153 1169 Blackwell Munksgaard No claim to original US government works Journal compilation C 2006 The American Society of Transplantation and the
More informationUric acid and CKD. Sunil Badve Conjoint Associate Professor, UNSW Staff Specialist, St George
Uric acid and CKD Sunil Badve Conjoint Associate Professor, UNSW Staff Specialist, St George Hospital @Badves Case Mr J, 52 Male, referred in June 2015 DM type 2 (4 years), HTN, diabetic retinopathy, diabetic
More informationCHAPTER 5 RENAL TRANSPLANTATION. Editor: Dr Rosnawati Yahya
CHAPTER 5 Editor: Dr Rosnawati Yahya Expert Panels: Dr Rosnawati Yahya Dr Ng Kok Peng Dr Suryati Binti Yakaob Dr Mohd Zaimi Abd Wahab Dr Yee Seow Ying Dr Wong Hin Seng Contents 5. Stock and Flow of Renal
More informationAccess and Outcomes Among Minority Transplant Patients, , with a Focus on Determinants of Kidney Graft Survival
American Journal of Transplantation 2010; 10 (Part 2): 1090 1107 Wiley Periodicals Inc. Special Feature No claim to original US government works Journal compilation C 2010 The American Society of Transplantation
More informationApolipoprotein L1 nephropathy risk variants associate with HDL subfraction concentration in African Americans
FTY720 and renal transplantation 3805 therapeutic advantage and no significant advantage in AEs or SAEs compared to MMF-based standard treatment regimen. Renal function post-transplantation was comparable
More informationDiltiazem use in tacrolimus-treated renal transplant recipients Kothari J, Nash M, Zaltzman J, Prasad G V R
Diltiazem use in tacrolimus-treated renal transplant recipients Kothari J, Nash M, Zaltzman J, Prasad G V R Record Status This is a critical abstract of an economic evaluation that meets the criteria for
More informationKidney Disease in HIV. Kidney Disease in HIV: An Update for Ryan White Providers
Kidney Disease in HIV: An Update for Ryan White Providers Christina M. Wyatt, MD Assistant Professor Mount Sinai School of Medicine New York, New York FORMATTED: 11/16/2015 Learning Objectives After attending
More informationMANAGEMENT CALL TO DISCUSS LONGER-TERM IMPROVEMENTS IN KIDNEY FUNCTION WITH BARDOXOLONE
MANAGEMENT CALL TO DISCUSS LONGER-TERM IMPROVEMENTS IN KIDNEY FUNCTION WITH BARDOXOLONE Introduction Substantial body of prior CKD clinical data characterizes Bard s unique profile Bard has demonstrated
More informationMarginal donors: Young vs. Old
Marginal donors: Young vs. Old Why we should prefer older donors Geir Mjøen, Oslo, Norway Long term risks in kidney donors Interpretation Consequences Recommendation Kidney donors Donors are healthy at
More informationTransplant Success in Sensitized Patients Receiving a Standardized Desensitization Therapy: 3 Year Outcomes
Transplant Success in Sensitized Patients Receiving a Standardized Desensitization Therapy: 3 Year Outcomes INTRODUCTION In patients awaiting a transplant, having antibodies reactive to HLA antigens present
More informationDiabetes, Obesity and Heavy Proteinuria
Diabetes, Obesity and Heavy Proteinuria Clinical Case 41 yo Black woman with heavy proteinuria History 2014: noted to have proteinuria on routine lab testing (1.1g/g). 1+ edema. Blood pressure has been
More informationRENAL EVENING SPECIALTY CONFERENCE
RENAL EVENING SPECIALTY CONFERENCE Harsharan K. Singh, MD The University of North Carolina at Chapel Hill Disclosure of Relevant Financial Relationships No conflicts of interest to disclose. CLINICAL HISTORY
More informationFor more information about how to cite these materials visit
Author(s): Silas P. Norman, M.D., 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution Noncommercial Share Alike 3.0 License: http://creativecommons.org/licenses/by-nc-sa/3.0/
More informationKidney transplantation 2016: current status and potential challenges
Kidney transplantation 2016: current status and potential challenges 15/12/2016 BVN-SBN : State-of-the-Art on Kidney Transplantation Patrick Peeters Ghent University Hospital, Belgium Challenges in 2016
More informationChronic Kidney Disease (CKD) Stages. CHRONIC KIDNEY DISEASE Treatment Options. Incident counts & adjusted rates, by primary diagnosis Figure 2.
Chronic Kidney Disease (CKD) Stages Stage 1 GFR > 90 (evidence of renal disease) Stage 2 GFR 60-89 Stage 3 GFR 30-59 Stage 4 GFR 15-29 Stage 5 GFR
More informationAssociation Analysis of the Reticulon 1 Gene in End-Stage Kidney Disease
American Journal of Nephrology Original Report: Patient-Oriented, Translational Research Received: August 26, 2015 Accepted: September 16, 2015 Published online: October 24, 2015 Association Analysis of
More informationManagement of Hypertension. M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine
Management of Hypertension M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine Disturbing Trends in Hypertension HTN awareness, treatment and control rates are decreasing
More informationDiabetes Mellitus GUIDELINES UNGRADED SUGGESTIONS FOR CLINICAL CARE IMPLEMENTATION AND AUDIT BACKGROUND
Diabetes Mellitus Date written: November 2011 Author: Scott Campbell GUIDELINES a. We recommend that diabetes should not on its own preclude a patient from being considered for kidney transplantation (1D).
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. ACE Inhibitor and Angiotensin II Antagonist Combination Treatment GUIDELINES
ACE Inhibitor and Angiotensin II Antagonist Combination Treatment Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES No recommendations possible based on Level
More informationCurrent status of kidney and pancreas transplantation in the United States,
American Journal of Transplantation 25; 5 (Part 2): 94 915 Blackwell Munksgaard Blackwell Munksgaard 25 Current status of kidney and pancreas transplantation in the United States, 1994 23 Gabriel M. Danovitch
More informationchapter seven transplantation page
chapter seven There been times that I thought I couldn t last for long But now I think I m able to carry on It s been a long, a long time coming But I know a change gonna come, oh yes it will Sam Cooke,
More informationLong-term prognosis of BK virus-associated nephropathy in kidney transplant recipients
Original Article Kidney Res Clin Pract 37:167-173, 2018(2) pissn: 2211-9132 eissn: 2211-9140 https://doi.org/10.23876/j.krcp.2018.37.2.167 KIDNEY RESEARCH AND CLINICAL PRACTICE Long-term prognosis of BK
More informationRenal Transplantation: Allocation challenges and changes. Renal Transplantation. The Numbers 1/13/2014
Renal Transplantation: Allocation challenges and changes Mark R. Wakefield, M.D., F.A.C.S. Associate Professor of Surgery/Urology Director Renal Transplantation Renal Transplantation Objectives: Understand
More informationQuantification of the Early Risk of Death in Elderly Kidney Transplant Recipients
Wiley Periodicals Inc. C Copyright 2012 The American Society of Transplantation and the American Society of Transplant Surgeons Quantification of the Early Risk of Death in Elderly Kidney Transplant Recipients
More informationPrevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan
Prevention And Treatment of Diabetic Nephropathy MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan Prevention Tight glucose control reduces the development of diabetic nephropathy Progression
More informationUser Guide. A. Program Summary B. Waiting List Information C. Transplant Information
User Guide This report contains a wide range of useful information about the kidney transplant program at (FLMR). The report has three main sections: A. Program Summary B. Waiting List Information The
More informationJames E. Cooper, M.D. Assistant Professor, University of Colorado at Denver Division of Renal Disease and Hypertension, Kidney and PancreasTransplant
James E. Cooper, M.D. Assistant Professor, University of Colorado at Denver Division of Renal Disease and Hypertension, Kidney and PancreasTransplant Program Has no real or apparent conflicts of interest
More informationMYH9 is a major-effect risk gene for focal segmental glomerulosclerosis
MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis Jeffrey B Kopp 1,17, Michael W Smith 2,16,17, George W Nelson 2,17, Randall C Johnson 2, Barry I Freedman 3, Donald W Bowden 3, Taras
More informationMr. I.K 58 years old
Mr. I.K 58 years old Hospitalized because of marked pitting peripheral edema (bilateral crural and perimalleolar edema) and uncontrolled blood pressure (BP 150/100 mmhg under treatment). since age 54 years
More informationChronic kidney disease (CKD) is a complex
IN THE LITERATURE The Genetic Basis of Kidney Disease Risk in African Americans: MYH9 as a New Candidate Gene Commentary on Kopp JB, Smith MW, Nelson GW, et al: MYH9 is a major-effect risk gene for focal
More informationALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic
1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker
More informationTransplantation: Year in Review
Transplantation: Year in Review Alexander Wiseman, MD Medical Director, Kidney and Pancreas Transplant Program Associate Professor, Division of Renal Diseases and Hypertension University of Colorado Outline:
More informationSGLT2 inhibition in diabetes: extending from glycaemic control to renal and cardiovascular protection
SGLT2 inhibition in diabetes: extending from glycaemic control to renal and cardiovascular protection Hiddo Lambers Heerspink Department of Clinical Pharmacy and Pharmacology University Medical Center
More informationIncidence of Rejection in Renal Transplant Surgery in the LVHN Population Leading to Graft Failure: 6 Year Review
Incidence of Rejection in Renal Transplant Surgery in the LVHN Population Leading to Graft Failure: 6 Year Review Jessica Ludolph 1 Lynsey Biondi, MD 1,2 and Michael Moritz, MD 1,2 1 Department of Surgery,
More informationThe New Kidney Allocation System: What You Need to Know. Quality Insights Renal Network 3 Annual Meeting October 2, 2014
The New Kidney Allocation System: What You Need to Know Quality Insights Renal Network 3 Annual Meeting October 2, 2014 Pre Dialysis Era Dialysis Status in USA 500,000 patients on dialysis in 2013 100,000
More informationDisparities in Transplantation Caution: Life is not fair.
Disparities in Transplantation Caution: Life is not fair. Tuesday October 30 th 2018 Caroline Rochon, MD, FACS Surgical Director, Kidney Transplant Program Hartford Hospital, Connecticut Outline Differences
More informationDoes Kidney Donor Risk Index implementation lead to the transplantation of more and higher-quality donor kidneys?
Nephrol Dial Transplant (2017) 32: 1934 1938 doi: 10.1093/ndt/gfx257 Advance Access publication 21 August 2017 Does Kidney Donor Risk Index implementation lead to the transplantation of more and higher-quality
More informationPeter Chang,* Jagbir Gill,* James Dong,* Caren Rose,* Howard Yan,* David Landsberg,* Edward H. Cole, and John S. Gill*
Article Living Donor Age and Kidney Allograft Half-Life: Implications for Living Donor Paired Exchange Programs Peter Chang,* Jagbir Gill,* James Dong,* Caren Rose,* Howard Yan,* David Landsberg,* Edward
More informationRECURRENT AND DE NOVO RENAL DISEASES IN THE ALLOGRAFT. J. H. Helderman,MD,FACP,FAST
RECURRENT AND DE NOVO RENAL DISEASES IN THE ALLOGRAFT J. H. Helderman,MD,FACP,FAST Vanderbilt University Medical Center Professor of Medicine, Pathology and Immunology Medical Director, Vanderbilt Transplant
More informationRecurrent Diseases in the Transplant. Simin Goral MD University of Pennsylvania Medical Center Philadelphia, Pennsylvania
Recurrent Diseases in the Transplant Simin Goral MD University of Pennsylvania Medical Center Philadelphia, Pennsylvania Case #1 21-year-old male, was on hemodialysis since September 2005 History of nephrotic
More informationUSRDS UNITED STATES RENAL DATA SYSTEM
USRDS UNITED STATES RENAL DATA SYSTEM Chapter 8: Pediatric ESRD 1,462 children in the United States began end-stage renal disease (ESRD) care in 2013. 9,921 children were being treated for ESRD on December
More informationQUICK REFERENCE FOR HEALTHCARE PROVIDERS
KEY MESSAGES 1 SCREENING CRITERIA Screen: Patients with DM and/or hypertension at least yearly. Consider screening patients with: Age >65 years old Family history of stage 5 CKD or hereditary kidney disease
More informationLiterature Review: Transplantation July 2010-June 2011
Literature Review: Transplantation July 2010-June 2011 James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver Kidney Transplant Top 10 List: July Kidney
More informationCardiovascular Risk Reduction in Kidney Transplant Recipients
Cardiovascular Risk Reduction in Kidney Transplant Recipients Rainer Oberbauer R.O. AUG 2010 CV Mortality in ESRD compared to the general population R.O.2/32 Modified from Foley et al. AJKD 32 (suppl3):
More informationCalcineurin inhibitors in HLA-identical living related donor kidney transplantation
Nephrol Dial Transplant (2014) 29: 209 218 doi: 10.1093/ndt/gft447 Calcineurin inhibitors in HLA-identical living related donor kidney transplantation ABSTRACT Priya S. Verghese 1, Ty B. Dunn 2, Srinath
More informationChronic renal histological changes at implantation and subsequent deceased donor kidney transplant outcomes: a single-centre analysis
Chronic renal histological changes at implantation and subsequent deceased donor kidney transplant outcomes: a single-centre analysis Benedict Phillips 1, Kerem Atalar 1, Hannah Wilkinson 1, Nicos Kessaris
More informationTREAT THE KIDNEY TO SAVE THE HEART. Leanna Tyshler, MD Chronic Kidney Disease Medical Advisor Northwest Kidney Centers February 2 nd, 2009
TREAT THE KIDNEY TO SAVE THE HEART Leanna Tyshler, MD Chronic Kidney Disease Medical Advisor Northwest Kidney Centers February 2 nd, 2009 1 ESRD Prevalent Rates in 1996 per million population December
More information